期刊文献+

紫杉类药物温敏纳米胶束的小鼠LD_(50)及其毒性差异 被引量:5

The LD_(50) and toxic defference of paclitaxel and docetaxel thermosensitive nano-micelle
下载PDF
导出
摘要 目的研究紫杉醇(Pac)和多希紫杉醇(Doc)温敏纳米胶束的急性毒性作用及其在结合和未结合热疗情况下的毒性差异。方法用不同剂量Doc和Pac温敏纳米胶束对昆明鼠行尾静脉注射,每个剂量分为热疗和非热疗组,观察小鼠用药后的急性毒副反应,计算半数致死量(LD50)。分别以两种药物最大耐受剂量对相应实验组行小鼠尾静脉注射(对照组给予等剂量生理盐水),测定外周血的白细胞和血小板。结果Doc温敏纳米胶束热疗和非热疗时小鼠尾静脉注射的LD50分别为(330.94±23.58)mg/kg和(278.07±19.81)mg/kg,Pac温敏纳米胶束的LD50分别为(104.18±5.85)mg/kg和(95.50±5.10)mg/kg。Pac和Doc均可以引起外周血白细胞和血小板显著降低;而两种药物的温敏纳米胶束对外周血白细胞和血小板的影响较小,且热疗比非热疗时影响更小。结论Pac和Doc温敏纳米胶束的急性毒性和对外周血白细胞和血小板的影响小于临床上常用的Pac和Doc注射液,且热疗时的毒性更小。 Objective To study the acute toxicity of paclitaxel (Pac) and docetaxel (doc) thermosensitive nano-micelle with and without hyperthermia. Methods Various doses of thermosensitive Pac and Doc nano-micelles were injected into the Kunming mice through caudal veins with and without hyperthermia. The 50% lethal dose (LD50) was calculated. White blood cells and platelet counts of peripheral blood were observed. Results The LD50 values of the Doc thermosensitive nano-micelles in mice with and without thermotherapy were (300.94±23.58) and (278.07±19.81) mg/kg, which of the Pac ( 104.18 ± 5.85 ) and (90. 50 ± 5.10) mg/kg, respectively. Pac and Doc reduced significantly the counts of white blood cell and platelet in peripheral blood, but the thermosensitive Pac and Doc nano±micelles did not. Conclusion The acute toxicity and side effects of thermosensitive Pac and Doc nano-micelles are less than those of Pac and Doc injection, especially with thermotherapy.
出处 《江苏医药》 CAS CSCD 北大核心 2008年第1期56-58,共3页 Jiangsu Medical Journal
基金 国家自然科学基金资助项目(30670958)
关键词 紫杉醇 多希紫杉醇 温敏纳米胶束 半数致死量 Paclitaxel Docetaxel Thermosensitive nano-micelle LD50
  • 相关文献

参考文献10

  • 1Zhang X,Liu YG.Toxicology[M].Beijing:the Beijing Med ical University and Chinese Xiehe Medical University United Publication House,1997:217-231.
  • 2Kim SC,Kim DW,Shim YH,et al.In vivo evaluation of polymeric micellar paclitaxel formulation:toxicity and efficacy[J].J Control Release,2001,72(1-3):191-202.
  • 3Bissery MC.Preclinical pharmacology of docetaxel[J].Eur J Cancer,1995,31(Suppl 14):1-6.
  • 4Guastalla JP,Dieras V.The taxanes:toxicity and quality of life consideration in advanced ovarian caner[J].Br J Cancer,2003:89(13):16-22.
  • 5Singla AK,Garg A,Aggarwal D,et al.Paclitaxel and its formulation[J].Int J Pharm,2002,235(1-2):179-192.
  • 6Gradishar WJ,Tjulandin S,Davidson N,et al.Phase Ⅲ trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer[J].Journal of Clinical Oncology,2005,23 (31):7794-7803.
  • 7Langer CJ.CT2103:emerging utility and therapy for solid tumours[J].Expert Opinion on Investigational Drugs,2004,13(11):1501-1508.
  • 8Kopecek J,Kopeckova P,Minko T,et al.Water soluble polymers in tumor targeted delivery[J].J Control Release,2001,74(1-3):147-158.
  • 9王元元,胡锦,董万利,蒋觉安.靶向血管内皮生长因子和神经生长因子的shRNA真核表达载体的构建与鉴定[J].江苏医药,2006,32(5):444-447. 被引量:1
  • 10Sharma A,Mayhew E,Bolicsak L,et al.Activity of paclitaxel liposome formulations against human ovarian tumor xenografts[J].Int J Cancer,1997,71(1):103-107.

二级参考文献1

同被引文献99

引证文献5

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部